Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells
© The Author(s). 2017
Received: 17 October 2016
Accepted: 18 January 2017
Published: 31 January 2017
Breast cancer is the major cause of cancer-related mortality in women. It is thought that quiescent stem-like cells within solid tumors are responsible for cancer maintenance, progression and eventual metastasis. We recently reported that the chemokine receptor CCR7, a multi-functional regulator of breast cancer, maintains the stem-like cell population.
This study used a combination of molecular and cellular assays on primary mammary tumor cells from the MMTV-PyMT transgenic mouse with or without CCR7 to examine the signaling crosstalk between CCR7 and Notch pathways.
We show for the first time that CCR7 functionally intersects with the Notch signaling pathway to regulate mammary cancer stem-like cells. In this cell subpopulation, CCR7 stimulation activated the Notch signaling pathway, and deletion of CCR7 significantly reduced the levels of activated cleaved Notch1. Moreover, blocking Notch activity prevented specific ligand-induced signaling of CCR7 and augmentation of mammary cancer stem-like cell function.
Crosstalk between CCR7 and Notch1 promotes stemness in mammary cancer cells and may ultimately potentiate mammary tumor progression. Therefore, dual targeting of both the CCR7 receptor and Notch1 signaling axes may be a potential therapeutic avenue to specifically inhibit the functions of breast cancer stem cells.
Despite significant recent advances in breast cancer treatment, breast cancer is still the major cause of cancer-related death in females worldwide. Resistance to radiation and chemotherapy, together with unpredictable recrudescence, are the most challenging issues in clinical practice. Significant evidence has accumulated in recent years to implicate cancer stem-like cells (CSCs) as the main perpetuators of cancer recurrence and therapy resistance in mammary and other tumors, as this cell population exhibits stem cell-like characteristics of self-renewal, quiescence and the ability to differentiate into various cell lineages [1, 2]. Therefore, targeting alterations acquired by CSCs in stemness-related signaling pathways has been proposed as an effective therapeutic strategy to counteract current treatment shortfalls in breast cancer management. However, CSC regulatory mechanisms remain largely undiscovered.
Chemokine receptors and their ligands have been implicated in numerous aspects of breast malignancy . The chemokine receptor CCR7 and its ligands CCL19 and CCL21 have been associated with metastasis, poor survival, invasion and cell migration in primary tumors and breast cancer experimental models [4–6]. We have recently shown that CCR7 regulates stem cell-like activity in primary mammary tumors in mice and humans , and sought to understand how CCR7-mediated stemness interacts with and/or is influenced by recognized stem cell-related signaling pathways.
The Notch pathway is one of the major signaling axes in embryonic and adult stem cell homeostasis and has a critical role in regulating proliferation, differentiation, apoptosis, cell-cell communication and other multiple functions [8, 9]. Notch receptors are proteolytically cleaved in a two-step process, releasing the intracellular domain that translocates to the nucleus and acts as a transcriptional cofactor for various genes including those mediating cell fate . A cancer-specific role of the Notch axis has also been extensively studied in both solid and blood neoplasms, and numerous inhibitors of γ-secretase – the enzyme that cleaves and hence activates Notch signaling — are now being trialed in human patients as anti-cancer drugs [11, 12]. Notably, Notch has been reported to play both oncogenic and tumor-suppressive roles depending on the cell type and tissue context , thus warranting further investigation into molecular determinants of the tumor-promoting or tumor-inhibiting arms of this complex, multifaceted signaling pathway.
Signaling through the Notch axis has been reported to crosstalk with multiple other pathways including numerous oncogenic mediators, such as Wnt effectors , the Hedgehog pathway, cytokines, kinases and growth factors in mammary and other cancers [14, 15]. Of note is the intersection between the epidermal growth factor receptor (EGFR) system and Notch pathway that has been proposed as a mechanism for trastuzumab resistance in HER2-positive tumors, and thus a route for therapeutic intervention . Effectively, the identification of specific crosstalk networks of Notch that govern growth and differentiation of mammary cancer cells may provide new opportunities for developing effective inhibitors of tumor relapse and metastasis.
As Notch pathway members have been implicated in maintenance of stem cell pools within mammary tumors [17–19], and having previously found that activation of CCR7-mediated signaling also promotes stemness , we hypothesized that these pathways may interact within breast CSC pools to enhance and maintain tumor cell stemness properties. Using the MMTV-PyMT mouse model, we show here that CCR7 and Notch1 cooperate and crosstalk within transformed mammary stem cell-like compartments, indicating that the CCR7-Notch axis may be a potential target for therapeutic intervention in breast cancer.
Materials and methods
MMTV-PyMT; Ccr7 WT (referred to as PyMT-Ccr7 WT) and MMTV-PyMT; Ccr7 −/− (referred to as PyMT-Ccr7 −/−) mice on a pure C57BL/6 background were generated and described previously . The University of Adelaide institutional animal ethics committee approved all protocols.
Mammary cell extraction
Mammary epithelial cell extraction was performed as described . Briefly, mouse mammary glands/tumors were dissected, manually dissociated and then digested in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 1 mg/ml collagenase, 100U/ml hyaluronidase (both from Worthington) and 2% foetal calf serum for 3 h at 37 °C. Resultant organoids were digested a further 15 min with 6U/ml dispase (Gibco) and 12U/ml DNase I (Merck) at 37 °C. Cells were filtered through a 70 μm nylon mesh to obtain a single cell suspension.
Mammosphere cultures were established by seeding freshly extracted mammary cells in complete sphere medium (1:1 volumes of DMEM and Ham’s F12 nutrient mix (Gibco) supplemented with 1× B27 (Invitrogen), 10 ng/ml epidermal growth factor (R & D Systems), 20 ng/ml basic fibroblast growth factor (R & D Systems), 4 ng/ml heparin (Sigma Aldrich), and 1% penicillin-streptomycin) to polyhema-coated plates. After 7 days, mammospheres were passaged by centrifuging at 200xg for 5 min, resuspended in trypsin/EDTA and triturated through a 19G needle to break up colonies. Cells were filtered through 70 μm and washed extensively before re-seeding for secondary culture in complete sphere medium. For all assays, secondary cultures were analyzed. Where specified, spheres were cultured in the presence of γ-secretase inhibitor RO4929097 (SelleckChem) at 50nM, Wnt/β-catenin inhibitor XAV-939 (SelleckChem) at 1 μM, CCL19 at 200 ng/ml, and CCL21 at 10 ng/ml. For analysis of mammosphere-forming efficiency, secondary spheres were assessed for number of spheres formed per cells seeded.
Flow cytometry and FACS
Flow cytometry/FACS was carried out by blocking for non-specific binding for 15 min at room temperature in mouse γ-globulin in PBS/0.5% bovine serum albumin (BSA) followed by immunostaining for 30–45 min on ice in PBS/0.5% BSA. Primary anti-mouse antibodies used were anti-Notch1ECD-APC, biotinylated anti-Notch1ICD (eBioscience), anti-CD24-PE, anti-CD29-PE, anti-CCR7-AlexaFluor647 (BD Biosciences), anti-CD24-FITC, anti-CD24-PE/Cy5 (Life Technologies), anti-CD29-FITC, anti-CD29-AlexaFluor647, anti-Jagged1-PE and anti-DLL1-AlexaFluor647 (BioLegend). For Notch1ICD, cells were permeabilized prior to labelling followed by detection using streptavidin-AlexaFluor488 (BD Biosciences) in PBS/0.5% BSA for 30 min on ice. Fluorescence-minus-one (FMO) controls for each antigen in multi-color analysis were used for negative gating. MFI = mean fluorescence intensity.
Proteins were separated by 10% SDS-PAGE and immobilized onto nitrocellulose membrane. Western analysis was performed as previously described . The γ-secretase inhibitor RO4929097 (SelleckChem) was used at 50nM and CCL19 at 200 ng/ml and times of treatment are specified in the figures and figure legends. Primary antibodies used were anti-Notch1 ICD (Abcam), anti-Hes1 (R & D Systems), anti-phospho-ERK, anti-ERK1/2 (both from Cell Signaling Technology) and anti-β-Actin (Sigma-Aldrich). Band intensities were calculated using Image J.
Cyclic AMP analysis
cAMP levels were measured using an AlphaScreen cAMP Assay Kit (Perkin-Elmer) as per manufacturer’s instructions. The γ-secretase inhibitor RO4929097 (SelleckChem) was used at 50nM, CCL19 at 200 ng/ml, and CCL21 at 10 ng/ml. Cells were treated for 30 min before analysis.
Forward Primer 5′–3′
Reverse Primer 5′–3′
Data are mean ± SEM and results are representative of at least 3 independent experiments. Significant statistical differences were estimated using Student’s t-tests or ANOVA and significant associations between CCR7 and Notch1 were identified using Pearson correlation coefficients. P-values were used to denote statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001.
CCR7 activates the Notch1 signaling pathway in mammary cancer stem-like cells
Notch mediates CCR7-promoted stemness in mammary cancer cells
As Notch activation requires proteolytic cleavage by γ-secretase, we utilized the γ-secretase inhibitor RO4929097 (previously used in breast cancer studies to inhibit Notch signaling ) to examine the effect of CCR7 on mammary cancer stem cells in the context of Notch activity blockade. The effect of RO4929097 in secondary PyMT-Ccr7 WT mammospheres was first verified by examining Hes1 expression, which was significantly reduced by addition of the inhibitor (Additional File 1: Figure S2a). Notably, we found that treatment with RO4929097 did not affect expression of CCR7 or its ligands CCL19 and CCL21 (Additional File 1: Figure S2b–d), in contrast with other studies in leukemic cells .
To further confirm that the CCR7 pathway interacts with Notch signaling, we analyzed mammosphere growth after addition of CCL19 and CCL21 with and without RO4929097. We observed that blocking γ-secretase significantly inhibited CCL19-mediated phosphorylation of ERK, an effector of CCR7 signaling that is not downstream of Notch itself (Fig. 3b). Notch also affected the ability of CCR7 to stimulate mammosphere formation. In concordance with a previous study  RO4929097 reduced secondary mammosphere formation. The addition of CCL19 or CCL21 was not sufficient to restore mammosphere formation to levels seen with chemokine stimulation alone (Fig. 3c), suggesting that inhibition of Notch inhibits the stemness-promoting function of CCR7. However, mammosphere formation was partially rescued, indicating that there are other Notch-independent pathways in play in this context.
We observed that the other major signaling pathway previously implicated in stem cell maintenance, Wnt/β-catenin , did not impact upon CCR7-mediated stemness as the Notch pathway appears to. Specifically, while inhibition of Wnt signaling with the specific inhibitor XAV-939 significantly decreased sphere-forming ability and hence stemness properties in primary PyMT-expressing tumor cells as expected , addition of the CCR7 ligand CCL21 to XAV-939 treated cells was sufficient to restore sphere formation to that seen when stimulated with CCL21 alone (Additional File 1: Figure S3), thus demonstrating that the Wnt pathway is not involved in CCR7-mediated regulation of stem cell maintenance.
These data show that the function of CCR7 in promoting the stemness of mammary tumor cells is partly mediated through Notch signaling. Although CCR7 regulates Notch1 activation in MMTV-PyMT tumor cells, the two pathways likely cooperate to promote CSC activity.
Despite advances in clinical treatment of breast cancer, recurrence remains a significant problem due to the survival of quiescent cancer stem cells. Novel combination therapies against CSCs, acting as adjuvants together with conventional approaches, are therefore needed. We previously demonstrated that the chemokine receptor CCR7 promotes mammary tumorigenesis via amplification of stem-like cells , and we now show here that crosstalk between Notch and CCR7 signaling promotes breast cancer stemness and may be a potential target for these new therapies.
Notch can have opposing roles depending on biological context, with Notch1 activation shown to both perpetuate and inhibit cell differentiation . Notch also regulates, and is regulated by, different chemokine receptors. In acute lymphoblastic leukemia, Notch1 regulates cell proliferation and migration through CCR5 and CCR9 , and in multiple myeloma Notch regulates CXCR4 . While no functional crosstalk between the two pathways has been reported so far, it was suggested that Notch activation up-regulates CCR7 expression in leukemic cells . However, in TCR-activated peripheral blood mononuclear cells CCR7 expression was slightly increased following Notch inhibition with RO4929097 . In breast cancer, CCL2 secreted from cancer-associated fibroblasts induces a CSC phenotype by activating Notch signaling, highlighting the concept that crosstalk may exist between the two axes . Plausibly, the interplay between CCR7 and Notch is adaptable in different systems.
In this study, we have demonstrated that the deletion of CCR7 significantly decreases levels of activated Notch1, and conversely, stimulation of the CCR7 pathway increases Notch receptor activation and expression of downstream target genes. We did not find any substantial Notch-mediated regulation of CCR7 receptor or ligand expression but observed a significant crosstalk at the functional level, which was not seen with the other major signaling pathway involved in stem cell maintenance, Wnt/β-catenin . Notably, unlike other cellular types such as lymphocytes that display differential-ligand induced CCR7 signaling and functional events  the observed CCR7 effect upon stemness is not ligand-specific, as we observed similar results for both CCL19 and CCL21.
Importantly, these findings may be translatable to human disease, as analysis of a published database available in Oncomine  showed that expression of CCR7 and Notch1 are significantly correlated in primary human breast cancers, particularly in higher grade tumors (Additional File 1: Figure S4). Although Notch proteins are known to regulate stemness, and CCR7 to promote tumorigenesis through a number of pathways, to the best of our knowledge this is the first study linking Notch1 to CCR7-dependent regulation of stem-like cells in mammary cancer. This novel phenomenon opens up the avenue for concurrent therapeutic targeting of these pathways. Antagonists towards CCR7 are capable of reducing stem-like cell content and activity , and γ-secretase inhibitors and antibodies that block the Notch pathway have also been shown to specifically target tumor-initiating cells [35, 36]. This approach may therefore be a new opportunity for targeting evasive cancer stem cells to control breast cancer progression.
The authors are grateful to Associate Professor Michael Samuel for critique of the manuscript.
This work was supported in part by a Project Grant from the National Health and Medical Research Council, Australia. The funding body did not play a role in the design, analysis, interpretation of data or manuscript preparation for the study.
Availability of data and materials
STB designed the study, performed and analyzed the majority of experiments, and wrote the manuscript. KAG performed and aided in analysis of quantitative PCR experiments. CEG carried out all cell sorting experiments. JWF provided experimental and technical assistance in acquisition of data. SRM supervised the study and provided reagents. MK designed and supervised the study, performed experiments and wrote the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The University of Adelaide institutional animal ethics committee approved all mouse studies.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–28.View ArticlePubMedGoogle Scholar
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Palacios-Arreola MI, Nava-Castro KE, Castro JI, Garcia-Zepeda E, Carrero JC, Morales-Montor J. The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. J Immunol Res. 2014;2014:849720.View ArticlePubMedPubMed CentralGoogle Scholar
- Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16:664–73.View ArticlePubMedGoogle Scholar
- Cunningham HD, Shannon LA, Calloway PA, Fassold BC, Dunwiddie I, Vielhauer G, Zhang M, Vines CM. Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes in mice. Transl Oncol. 2010;3:354–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 2006;17:945–51.View ArticlePubMedGoogle Scholar
- Boyle ST, Ingman WV, Poltavets V, Faulkner JW, Whitfield RJ, McColl SR, Kochetkova M. The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells. Oncogene. 2016;35(1):105–15.Google Scholar
- Sale S, Lafkas D, Artavanis-Tsakonas S. Notch2 genetic fate mapping reveals two previously unrecognized mammary epithelial lineages. Nat Cell Biol. 2013;15:451–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–6.View ArticlePubMedGoogle Scholar
- Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123:2451–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, et al. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015;5:e350.View ArticlePubMedPubMed CentralGoogle Scholar
- Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Onco Targets Ther. 2013;6:943–55.PubMedPubMed CentralGoogle Scholar
- Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP, Brisken C. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A. 2006;103:3799–804.View ArticlePubMedPubMed CentralGoogle Scholar
- Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta. 1815;2011:197–213.Google Scholar
- Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015;21:955–61.View ArticlePubMedGoogle Scholar
- Baker AT, Zlobin A, Osipo C. Notch-EGFR/HER2 bidirectional crosstalk in breast cancer. Front Oncol. 2014;4:360.View ArticlePubMedPubMed CentralGoogle Scholar
- McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, Chambers AF. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res. 2011;9:834–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6:R605–615.View ArticlePubMedPubMed CentralGoogle Scholar
- Ling H, Sylvestre JR, Jolicoeur P. Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors. Oncogene. 2010;29:4543–54.View ArticlePubMedGoogle Scholar
- Boyle ST, Faulkner JW, McColl SR, Kochetkova M. The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages. Mol Cancer. 2015;14:115.View ArticlePubMedPubMed CentralGoogle Scholar
- Holland JD, Kochetkova M, Akekawatchai C, Dottore M, Lopez A, McColl SR. Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res. 2006;66:4117–24.View ArticlePubMedGoogle Scholar
- Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439:84–8.View ArticlePubMedGoogle Scholar
- Ma J, Lanza DG, Guest I, Uk-Lim C, Glinskii A, Glinsky G, Sell S. Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. Tumour Biol. 2012;33:1983–96.View ArticlePubMedGoogle Scholar
- Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012;134:495–510.View ArticlePubMedPubMed CentralGoogle Scholar
- Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, Klinakis A, Lukyanov Y, Tseng JC, Sen F, et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 2009;459:1000–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res. 2010;30:3853–67.PubMedGoogle Scholar
- Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346:1248012.View ArticlePubMedGoogle Scholar
- Zeng YA, Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell. 2010;6:568–77.View ArticlePubMedPubMed CentralGoogle Scholar
- Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M, Basile A, Locati M, Cobos E, Kast WM, et al. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol. 2012;226:713–22.View ArticlePubMedGoogle Scholar
- Mirandola L, Apicella L, Colombo M, Yu Y, Berta DG, Platonova N, Lazzari E, Lancellotti M, Bulfamante G, Cobos E, et al. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia. 2013;27:1558–66.View ArticlePubMedGoogle Scholar
- Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li AX, Wu X, Ye W, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012;72:2768–79.View ArticlePubMedPubMed CentralGoogle Scholar
- Raju R, Gadakh S, Gopal P, George B, Advani J, Soman S, Prasad TS, Girijadevi R. Differential ligand-signaling network of CCL19/CCL21-CCR7 system. Oxford: Database; 2015.Google Scholar
- Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.PubMedPubMed CentralGoogle Scholar
- Kondratyev M, Kreso A, Hallett RM, Girgis-Gabardo A, Barcelon ME, Ilieva D, Ware C, Majumder PK, Hassell JA. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2012;31:93–103.View ArticlePubMedGoogle Scholar
- Sharma A, Paranjape AN, Rangarajan A, Dighe RR. A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells. Mol Cancer Ther. 2012;11:77–86.View ArticlePubMedGoogle Scholar